Advanced search
Publication Cover
Infection and Drug Resistance Volume 14, 2021 - Issue
Submit an article Journal homepage
122
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Rarity of rpoB Mutations Outside the Rifampicin Resistance-Determining Region of Mycobacterium tuberculosis Isolates from Patients Responding Poorly to First-Line Tuberculosis Regimens in Beijing, China: A Retrospective Study

Jidong Guo1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-7026-5109
ORCID Icon,
Rongmei Liu1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China
,
Jin Shi1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China
,
Fengmin Huo2 National Clinical Laboratory on Tuberculosis, Beijing Key laboratory on Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China
,
Yuanyuan Shang3 Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China
,
Fen Wang2 National Clinical Laboratory on Tuberculosis, Beijing Key laboratory on Drug-resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China
,
Mengqiu Gao1 Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of ChinaCorrespondence[email protected]
&
Shanshan Li3 Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4475-4536
ORCID Icon show all
Pages 2607-2612 | Published online: 06 Jul 2021

Figures & data

Figure 1 Sequencing results of Xpert RIF-susceptible MTB rpoB genes of isolates from patients with poor clinical responses after 3 months of first-line regimen treatment.

Abbreviations: TB, tuberculosis; NTM, nontuberculous mycobacteria.
Figure 1 Sequencing results of Xpert RIF-susceptible MTB rpoB genes of isolates from patients with poor clinical responses after 3 months of first-line regimen treatment.

Figure 2 MICs of MTB isolates to rifampicin (A), rifapentine (B) and rifabutin (C).

Abbreviation: MIC, minimal inhibitory concentration.
Figure 2 MICs of MTB isolates to rifampicin (A), rifapentine (B) and rifabutin (C).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.